OBJECTIVE:To compare the efficacy and safety of preservation and reconstruction of vesicourethral supportive structures during laparoscopic radical prostatectomy (PRVUS-LRP) to the conventional LRP (Conv-LRP). METHODS:This retrospective study analyzed 106 patients with clinically localized prostate cancer (PCa) (cT1-2N0M0) who underwent LRP between August 2020 and June 2023. The patients were stratified into a PRVUS-LRP group (n = 52) and a Conv-LRP group (n = 54). The modified technique preserves the pelvic floor fascia, bladder neck, puboprostatic ligament, and functional urethral length via intrafascial excision, non-ligation of the dorsal vascular complex, modified posterior pelvic floor reconstruction, and anterior pelvic floor reconstruction. RESULTS:The operative times of the PRVUS-LRP and Conv-LRP groups were comparable (P > 0.05) but the former group experienced significantly greater estimated blood loss (160.6 ± 115.3 vs. 89.4 ± 55.3 mL; P < 0.001). The urinary continence (UC) rates at the 1-, 3-, and 6-month follow-ups were 50.0, 94.2, and 98.1% in the PRVUS-LRP group vs. 24.1, 77.8, and 92.6% in the Conv-LRP group. Significant intergroup differences that favored PRVUS-LRP were observed at 1 (P = 0.006) and 3 (P = 0.031) months, but the 6-month outcomes did not differ significantly (P = 0.383). No significant between-group differences were detected in terms of the positive surgical margin rate or biochemical recurrence. The cumulative summation curve started to decrease after 19 operations. CONCLUSION:PRVUS-LRP is a safe and effective modification that significantly enhances early UC recovery, without compromising oncological outcomes.

Vaccinia-related kinase 1 (VRK1) is a serine-threonine kinase involved in the proliferation and migration of various cancer cells. However, its role in prostate cancer (PCa), particularly in the development of therapeutic resistance, remains unclear. We established an androgen-independent PCa cell line derived from LNCaP prostate cancer cells and conducted transcriptome and proteome sequencing together with bioinformatic analyses of large clinical sample databases to investigate the potential role of VRK1 in PCa progression. The correlation between VRK1 and androgen receptor (AR) signaling was evaluated under simulated clinical treatment conditions. The effects of VRK1 on cell proliferation were assessed in vitro and in vivo using Cell Counting Kit-8 and colony formation assays. Additionally, proteome and transcriptome sequencing, combined with rescue experiments were performed to explore VRK1-regulated signaling pathways related to cell proliferation and therapeutic resistance. VRK1 expression was elevated during the progression of androgen-dependent prostate cancer to castration-resistant prostate cancer under therapeutic conditions, and high VRK1 expression was associated with a poor prognosis in patients with PCa. VRK1 was regulated by AR signaling, and its silencing suppressed PCa cell proliferation both in vitro and in vivo. VRK1 drove cell proliferation and therapeutic resistance in PCa by modulating yes-associated protein 1 (YAP1). VRK1 serves as a prognostic marker in PCa, regulated by AR signaling. VRK1 depletion inhibited cell proliferation both in vitro and in vivo, while elevated VRK1 upregulated YAP1, promoting cell proliferation and therapeutic resistance.

Myeloid-derived suppressor cells(MDSCs)constitute a crucial component of the immunosuppressive tumor micro-environment.1 Prostaglandin E2 receptor 4(EP4)is involved in regulating immunosuppressive MDSC differentiation and is emerging as a promising target for cancer immunotherapy.2 No EP4 antagonists have been approved for anti-tumor therapy,underscoring the urgent requirement for the dis-covery of novel EP4 antagonists.G protein and β-arrestin represent two classical downstream pathways for EP4.The inactivity of G protein and β-arrestin serves as a readout to indicate EP4 antagonism,providing a rationale for estab-lishing EP4 drug screening platforms.From a broad perspective on the history of G protein-coupled receptor(GPCR)drug discovery,using a β-arrestin-based drug screening strategy may offer greater advantages over G protein strategies,especially for the GPCRs that have not been proven on which G proteins they bind.Several cellular assays for the detection of GPCR/β-arrestin interaction have been established,including the PRESTO-Tango assay and fluorescent β-arrestin labeling assay.However,these assays are not suitable for the real-time dynamic detection of GPCR-β-arrestin signaling.In this study,we aimed to develop a novel real-time β-arrestin recruitment assay for EP4 re-ceptor and to identify a potent EP4 antagonist that could attenuate the immunosuppressive effects of MDSCs.

Background: Delta-like canonical notch ligand 4 (DLL4) is considered a potential prognostic gene for renal cell carcinoma (RCC). We assessed the molecular mechanisms and novel biomarkers associated with DLL4 during RCC development.Methods: Four gene expression profiles were downloaded from the GEO database. Differentially expressed genes (DEGs) were identified between RCC and normal renal samples, including common DEGs (co-DEGs). Thereafter, RCC-associated gene exploration was performed and a PPI network was constructed to identify the core genes. Survival analysis of core genes in the high expression group (H group) and low expression group (L group) was also performed. The key genes related to the core genes were investigated, and the miRNA-target genes and TFs-target genes were analyzed. Finally, the expres-sion levels of VEGFA, FLT1, EGLN3, and DLL4 in RCC and paracancerous tissues were determined.Results: A total of 11,867 DEGs and 622 co-DEGs were identified in this study, and 67 RCC-associated genes that were mainly enriched in signal transduction and angiogenesis function were further explored. VEGFA was identified as the core gene. Further, 30 DEGs and 9 DE-miRNAs were identified between the H and L groups. VEGFA was positively correlated with 19 genes, including EGLN3, FLT1, and DLL4. A total of 18 miRNA-target interactions, including miR-134-5p-DLL4, were obtained. VEGFA, FLT1, EGLN3, and DLL4 were significantly expressed in RCC tissues compared with paracancerous tissues.Conclusions: DLL4 may contribute to the development of RCC by participating in signal transduction and angiogenesis. VEGFA, FLT1, EGLN3, DLL4, and miR-134-5p may be novel biomarkers for RCC.

OBJECTIVE To evaluate the efficacy and safety of 1470-nm Diode Laser Enucleation of the Prostate (DiLEP) in patients with benign prostatic hyperplasia continuously receiving oral anticoagulants or antiplatelet drugs. METHODS From January 2016 to June 2017, 144 patients were submitted to 1470-nm DiLEP, including 49 (34.0%) continuously administered anticoagulants or antiplatelet drugs per os due to cardiac and/or cerebrovascular diseases (group A), while 95 (66.0%) were not (group B). Evaluation was performed preoperatively, and at postoperative 3, 6, and 12 months, respectively. Patient baseline features, operative data, perioperative complications, and postsurgical outcomes were assessed. RESULTS Both groups had comparable preoperative parameters, except age (77.3 +/- 7.5 vs 73.2 (+/-) 8.8 years, P = .007). Meanwhile, surgical time, sodium decrease, catheterization duration, and hospital stay markedly differed between the 2 groups. In comparison with group B, group A patients had statistically higher blood loss (14.9 +/- 7.3 g/L vs 10.2 +/- 7.0 g/L, P < .001) and increased bladder irrigation time (21.1 +/- 10.9 hours vs 16.1 +/- 9.0 hours, P = .004). One case required blood transfusion in group A, because of moderate anemia preoperatively. Both groups showed similar blood transfusion and complication rates. International Prostate Symptom Score, quality of life score, maximum flow rate, and postvoid residual were markedly improved in both groups at 3-, 6-, and 12-month follow-up postoperatively compared with baseline values. However, no statistically significant differences were observed between the 2 groups in various assessment parameters at follow-up (P > .05). CONCLUSION These findings demonstrated that 1470-nm DiLEP is efficient and safe in benign prostatic hyperplasia cases receiving continuous oral anticoagulant or antiplatelet drugs. Anticoagulation therapy did not significantly influence the results and complication rates. (C) 2020 Elsevier Inc.

Background KLF16, a member of the Kruppel-like factor (KLF) family, functions in the regulation of dopaminergic transmission, metabolism, and endocrinology. However, the role of KLF16 in prostate cancer (PCa) remains unknown. Methods We screened the expression of KLFs in PCa based on bioinformatics analysis. The protein levels of KLF16 in PCa specimens were confirmed by immunohistochemistry. Inhibiting KLF16 by RNA interference with shRNA was used to determine the effects of KLF16 on PCa cell growth in vitro and in vivo. RNA sequencing was used to investigate the signaling regulated by KLF16 in PCa. Bioinformatics analysis was also used to determine the possible correlations of KLF16 and signaling in PCa cohorts. Results Bioinformatics analysis showed that KLF16 may be required for PCa development. Notably, the expression of KLF16 was elevated in human PCa tissues. In vitro and in vivo experiments both demonstrated that depleting KLF16 significantly inhibited the growth of PCa cells. Downregulation of KLF16 significantly decreased the expression of MYC signaling in PCa cells. Furthermore, KLF16 expression was correlated with MYC signaling activity. Conclusion KLF16 was overexpressed in PCa tissues compared to normal tissues. KLF16 knockdown suppressed PCa cell growth in vitro and in vivo, and a deficiency of KLF16 inhibited activation of MYC signaling.

OBJECTIVE:To investigate the application of a metamorphic mechanism-based special dressing system (MMDS) in improving the prognosis and comfort of the patient after scrotal surgery.METHODS:We included 48 cases of scrotal surgery using the traditional method for postoperative dressing from June 2017 to June 2018 (the control group) and another 48 cases employing MMDS postoperatively from July 2018 to June 2019 (the MMDS group). We observed the differences between the two groups of patients in the incidence of scrotal edema, pain score, hospitalization days, patients' satisfaction, and dressing time.RESULTS:The scrotal edema score showed no statistically significant difference between the MMDS and control groups at 24 hours after operation (P > 0.05) but remarkably lower in the former than in the latter group at 48 hours (1.42 ± 0.5 vs 2.27 ± 0.7, P < 0.05) and 72 hours postoperatively (1.35 ± 0.2 vs 2.25 ± 0.7, P < 0.05). The MMDS group, compared with the controls, also exhibited a lower pain score (2.2 ± 1.0 vs 3.4 ± 1.5, P < 0.05), shorter hospitalization time (［5.96 ± 1.2］ vs ［9.13 ± 2.3］ d, P < 0.05) and higher satisfaction score (98.1 ± 1.6 vs 92.8 ± 2.8, P < 0.05), as well as shorter dressing time at 24, 48 and 72 hours after operation (P < 0.05).CONCLUSIONS:The metamorphic mechanism-based special dressing system is a safe, efficient, simple and feasible method for dressing after scrotal surgery, which can effectively promote recovery and improve the quality of life of the patients.

Objective: To investigate the effects of long-chain non-coding RNA EGFR-AS1 on the development and metastasis of renal cell carcinoma. Methods: EGFR-AS1 expression was detected in samples taken from 40 normal patients, comprising 40 renal parenchyma specimens and 40 renal carcinoma samples. The relationships between the expression of EGFR-AS1 in kidney cancer tissues and age, sex, tissue progression, TNM staging, and lymph node metastasis were analyzed. In vitro cell assay was conducted. EGFR-AS1 small interfering RNA was used to down-regulate the expression of EGFR-AS1 in renal cancer cells. Transwell assay was used to detect the invasive ability of interfering and undisturbed renal cancer cells. Cell scratch test was used to detect migration ability changes after EGFR-AS1 expression down-regulation in renal cancer cells. Results: In normal human kidney tissues, the expression of EGFR-AS1 was lower, while the expression level of EGFR-AS1 was higher in renal carcinoma. After analysis, it was found that the expression of EGFR-AS1 was significantly correlated with the TNM stage of renal carcinoma and whether lymph node metastasis had occurred (P<0.05). Transwell experiments showed that the transmembrane cell count of renal cancer cells after small interfering RNA interference was lower than that without interference (P<0.05); the cell scratch test showed the migration distance of small interference RNA in renal cancer cells after interference was shorter than that without interference. Conclusion: EGFR-AS1 is highly expressed in human renal carcinoma tissues and promotes the proliferation and infiltration of tumour cells.

Purpose: Sexual dysfunction in women with overactive bladder (OAB) syndrome has been an important topic, while the sexual satisfaction of partners has not been fully investigated. Our aim was to explore the association between the severity of OAB with female sexual dysfunction and sexual satisfaction of partners. Methods: A total of 323 patients with OAB recruited in our hospital were included in our study from September 2017 to March 2019. Data were collected by Overactive Bladder Symptom Score (OABSS) questionnaire, self-designed questionnaire for basic characteristics; Female Sexual Function Index (FSFI); and sexual satisfaction survey for sex partners of patients. χ2 test or 1-way ANOVA was used to compare the variables among groups. Logistic regression analysis was performed to analyze the severity of OAB with female sexual dysfunction and sexual satisfaction of partners. The correlations between different OABSS domains with female sexual dysfunction and sexual satisfaction of partners were assessed. Results: All the patients were classified into mild (n = 107), moderate (n = 98), severe (n = 118) OAB group based on OABSS. Most of the basic information were similar among groups, except for BMI, highest education, occupation, fertility, and history of pelvic floor surgery. After multiple factors correction, the severity of OAB, exercise frequency, and the history of pelvic floor surgery were statistically associated with the female sexual dysfunction and sexual satisfaction of partners. Urgency score was significantly correlated with female sexual dysfunction, and the urge incontinence was most significantly associated with the sexual satisfaction of partners. Conclusion: Severe OAB was closely associated with female sexual dysfunction and sexual satisfaction of partners. The urgency and urge incontinence should be focused for OAB management.

目的 探讨经尿道1 470 nm半导体激光前列腺汽化切除术联合腹腔镜下膀胱憩室切除术同期治疗前列腺增生合并膀胱憩室的可行性和优越性.方法 回顾性地分析自2017年8月至2018年2月我科收治的应用经尿道1 470 nm半导体激光前列腺汽化切除术联合腹腔镜下膀胱憩室切除术同期治疗前列腺增生合并膀胱憩室6例患者的临床资料.结果 6例手术均成功完成,无中转开放手术,平均手术时间为(206.3±19.54) (185～240)min,术中出血量平均为(69.2±18.01)(50～100)mL,术后平均膀胱冲洗时间为(15.8±5.67)(8～22)h,平均住院时间为(8.5±1.05)(7～10)d.术后3个月随访患者排尿症状明显改善,平均最大尿流率为(19.9±3.06)(16.8～25.2)mL/s,平均残余尿为(19.2±8.01)(10～30)mL,术后无相关并发症发生.结论 经尿道1 470 nm半导体激光前列腺汽化切除术联合腹腔镜下膀胱憩室切除术同期治疗前列腺增生合并膀胱憩室是一种安全、可行的手术方法,由于其手术创伤小、出血少、患者恢复快,具有一定的优越性.

Background POH1, a member of the JAMM domain containing deubiquitinases, functions in malignant progression of certain types of cancer. However, the role of POH1 in prostate cancer (PCa) remains unclear. Methods We performed RNA interference against the JAMM members in PC3 cells and analyzed cell proliferation. POH1 knockdown was established to evaluate the effects of POH1 on cell growth in vitro and in vivo. RNA-sequencing was utilized to explore the molecular details underlying the biological function of POH1 in PCa. The expression of POH1 in PCa tissues was detected by immunohistochemistry. The POH1 inhibitor capzimin was evaluated to explore whether pharmacologically inhibiting POH1 significantly affected PCa cell proliferation alone or enhanced the inhibitory efficacy of docetaxel and androgen deprivation. Results Functional analyses identified POH1 as a JAMM deubiquitinase that is required for PCa proliferation. Importantly, expression of POH1 was higher in human PCa tissues (PCas) than that in normal prostate tissues, and a positive correlation was detected between elevated POH1 expression and higher pathological grades in PCas. In vivo experiments further demonstrated that depleting POH1 significantly suppressed the growth of PCa cell xenografts. POH1 deficiency profoundly inhibited the expression of a set of genes involving the cell cycle and caused G0/G1 phase arrest. Furthermore, the POH1 inhibitor capzimin phenotypically recapitulated the effects of POH1 knockdown and improved the efficacy of docetaxel and androgen deprivation in PCa cells. Conclusions POH1 was overexpressed in PCas and was correlated with pathological grades in human PCas. Inhibiting POH1 by gene silencing or pharmacological inhibition with capzimin suppressed PCa cell growth. Exploring the inhibition of POH1 in combination with other drugs may provide a strategy to benefit patients with PCa.

Funding information Natural Science Foundation of Shanghai, Grant/Award Number: 18ZR1429800; Shanghai Rising‐Star Program, Grant/Award Number: 17QA1403700; The Fifth People`s Hospital of Shanghai, Fudan University, Grant/ Award Number: 2018WYZD02 Abstract Background: POH1, a member of the JAMM domain containing deubiquitinases, functions in malignant progression of certain types of cancer. However, the role of POH1 in prostate cancer (PCa) remains unclear. Methods: We performed RNA interference against the JAMM members in PC3 cells and analyzed cell proliferation. POH1 knockdown was established to evaluate the effects of POH1 on cell growth in vitro and in vivo. RNA‐sequencing was utilized to explore the molecular details underlying the biological function of POH1 in PCa. The expression of POH1 in PCa tissues was detected by immunohistochemistry. The POH1 inhibitor capzimin was evaluated to explore whether pharmacologically inhibiting POH1 significantly affected PCa cell proliferation alone or enhanced the inhibitory efficacy of docetaxel and androgen deprivation. Results: Functional analyses identified POH1 as a JAMM deubiquitinase that is required for PCa proliferation. Importantly, expression of POH1 was higher in human PCa tissues (PCas) than that in normal prostate tissues, and a positive correlation was detected between elevated POH1 expression and higher pathological grades in PCas. In vivo experiments further demonstrated that depleting POH1 significantly suppressed the growth of PCa cell xenografts. POH1 deficiency profoundly inhibited the expression of a set of genes involving the cell cycle and caused G0/G1 phase arrest. Furthermore, the POH1 inhibitor capzimin phenotypically recapitulated the effects of POH1 knockdown and improved the efficacy of docetaxel and androgen deprivation in PCa cells. Conclusions: POH1 was overexpressed in PCas and was correlated with pathological grades in human PCas. Inhibiting POH1 by gene silencing or pharmacological inhibition with capzimin suppressed PCa cell growth. Exploring the inhibition of

目的 比较使用封堵取石导管联合输尿管镜钬激光碎石术治疗输尿管上段结石的临床效果和安全性.方法 输尿管上段结石病人120例,随机分为两组,每组各60例,封堵器组采用封堵取石导管,无封堵器组不使用任何封堵装置组,行输尿管镜下钬激光碎石术,观察两组手术时间、碎石率及并发症发生情况.结果 封堵器组一期碎石成功率为93.3％,无封堵器组为78.3％,封堵器组术后住院时间为(2.5±0.4)天,无封堵器组(3.7±0.6)天;封堵器组术后随访无石率为96.7％,无封堵器组为86.7％,两组比较差异均有统计学意义(P<0.05).两组手术并发症比较差异无统计学意义(P>0.05).结论 输尿管镜下使用封堵取石导管联合钬激光碎石,可减少输尿管上段结石的漂移,提高结石清除率,缩短住院时间.

目的 探讨难治性高血压患者的临床特点.方法 纳入2012年1月～2013年12月于我院内分泌代谢科就诊的高血压患者320例,依据难治性高血压的诊断标准将其分为高血压组269例和难治性高血压组51例.收集两组患者的临床资料并进行比较分析.结果 难治性高血压患者占总高血压患者的15.9％ (51/320).难治性高血压组患者病程长于高血压组,收缩压(SBP)、舒张压(DBP)及醛固酮水平均高于高血压组(P＜0.05),而两组患者性别、年龄、体重指数(BMI)、心率、QT间期、血钾、血钠、二氧化碳结合力比较,差异均无统计学意义(P＞0.05).难治性高血压组使用可乐定、α-受体阻滞剂、螺内酯、氢氯噻嗪、吲达帕胺、血管紧张素受体Ⅱ阻断剂(ARB)及钙离子拮抗剂(CCB)患者比例均高于高血压组(P＜0.05),而两组间使用β-受体阻滞剂和血管紧张素转化酶抑制剂(ACEI)患者比例比较差异均无统计学意义(P＞0.05).难治性高血压组合并糖尿病、冠心病、慢性肾脏病、高尿酸血症、肾上腺CT见腺瘤改变患者比例及颈动脉内膜厚度高于高血压组(P＜0.05),而两组间合并血脂异常、脑卒中患者比例比较差异均无统计学意义(P＞0.05).结论 难治性高血压患者占总高血压患者的比例较高,且常合并多种心血管危险因素及心脏、肾脏、肾上腺疾病.

目的 评估国产醋酸去氨加压素片与原研药物治疗女性夜间多尿症的疗效及安全性.方法 96例女性夜间多尿症患者被随机分为2组,试验组给予国产醋酸去氨加压素片,每日睡前服用0.1 mg,共治疗8周.对照组给予进口原研醋酸去氨加压素片,剂量和疗程同试验组.治疗8周后,评价两组夜尿次数、夜尿量、夜间多尿指数、24 h排尿次数、24 h尿量、第一次觉醒睡眠时间等指标和治疗后肝肾功能异常率、血钠值异常率和残余尿量异常率.结果 经8周治疗,两组患者主要结局指标夜尿次数、夜尿量、夜间多尿指数及24 h排尿总次数、24 h尿量、第一次觉醒睡眠时间比较,差异均无统计学意义(P均＞0.05).组内比较:两组夜尿次数、夜尿量、夜间多尿指数、治疗前后比较差异均有统计学意义(P均＜0.05).以50岁为界做亚组分析,在不同亚组人群中,两种药物治疗效果无统计学差异(P＞0.05).两组均未发生明显不良反应.结论 国产醋酸去氨加压素片和进口原研药物治疗女性夜间多尿症近期疗效、安全性无统计学差异,可作为治疗女性夜间多尿症有效可选药物.

目的 探讨经尿道1 470 nm半导体激光前列腺剜除术(DiLEP)治疗体积＞80 mL的良性前列腺增生症(BPH)患者的临床疗效及安全性.方法 2016年1月至2018年1月复旦大学附属上海市第五人民医院为74例大体积BPH患者实施DiLEP术,收集这些患者临床资料进行回顾性分析,观察手术时间、膀胱持续冲洗时间、留置导尿时间、住院天数、术后血红蛋白及血清钠离子变化情况、手术并发症.术后3个月及6个月随访患者,评估膀胱残余尿量(PVR)、最大尿流率(Qmax)、国际前列腺症状评分(IPSS)、及生活质量评分(QoL)改善情况.结果 74例手术均成功完成,平均手术时间(104.9±25.1)min,平均膀胱冲洗时间(22.1±9.8)h,平均导尿时间(3.2±1.1)d,平均住院天数5～11(8.3±1.1)d,术后血红蛋白及血清钠离子浓度无明显下降.术后3个月、6个月患者PVR、Qmax、IPSS、QoL较术前明显改善(P＜0.05).术中无中转开放及TURP,无直肠、膀胱穿孔,无电切综合征(TURS),无明显出血,术后无输血术,无永久性尿失禁.结论 经尿道1 470 nm半导体激光前列腺剜除术治疗大体积前列腺增生疗效显著且安全性高,值得临床进一步推广及应用.

Purpose: As a typical hypervascular tumor, clear cell renal cell carcinoma (ccRCC) is the most common type of RCC. This study was aimed to explore the prognostic genes for ccRCC, focusing on the roles of vascular endothelial growth factor A (VEGFA) and Delta-like ligand 4 (DLL4) in the disease. Materials and methods: The mRNA-sequencing data of kidney renal clear cell carcinoma (KIRC) were obtained from The Cancer Genome Atlas (TCGA) database, including 469 tumor samples and 68 adjacent normal samples. Using limma package, differentially expressed genes (DEGs) were analyzed by differential expression and subgroup analyses and confirmed using validation dataset GSE53757. Followed by enrichment analysis, protein-protein interaction (PPI) network analysis and protein subcellular localization were performed using multifaceted analysis tool for human transcriptome tool, and Cytoscape software and InnateDB database, respectively. Moreover, survival analysis was conducted to identify key prognosis-associated genes. In addition, VEGFA and DLL4 levels were detected using real-time quantitative PCR (qRT-PCR). Results: A total of 1,984 DEGs were screened in the KIRC tumor samples. VEGFA was located in extracellular space and could interact with placental growth factor (PGF) and angiopoietin 2 (ANGPT2) in the PPI network. Subgroup analysis suggested that VEGFA was significantly upregulated in stages I, II, and III ccRCC tumor samples. Survival analysis showed that TIMP1 was among the top four prognosis-associated genes. qRT-PCR analysis confirmed that the expression levels of DLL4 and VEGFA were significantly upregulated in tumor samples. Conclusion: VEGFA and DLL4 might be prognostic genes for ccRCC. Besides, PGF, ANGPT2, and TIMP1 might also be related to the prognosis of ccRCC patients.

Objective It is to investigate the expression of vascular endothelial growth factor(VEGF)and delta-like ligand 4(DLL4)in renal cell carcinoma and their relationship with clinicopathological features and prognosis of renal cell carcinoma(RCC). Methods Paraffin specimens of 80 patients with renal cell carcinoma who underwent radical nephrecto-my for renal cell carcinoma were collected,and 30 cases of normal tissue adjacent to cancer were taken as control. The ex-pression of VEGF and DLL4 in cancer tissues and normal tissues adjacent to cancer were detected by immunohistochemical method. The patients were followed up for 5 years. The relationship between the pathological features and prognosis of VEGF,DDL4 and renal cell carcinoma patients was analyzed. Results The positive expression rates of VEGF and DLL4 in renal cell carcinoma were significantly higher than those in adjacent normal tissues(all P<0.05),and they were signifi-cantly correlated with clinical stage and lymph node metastasis(all P<0.05). The expression of VEGF in renal cell carci-noma was significantly correlated with the expression of DLL4(r=0.251,P=0.030). The 5-year survival rates of VEGF or DLL4 low expression group were significantly higher than those of the high expression group(all P<0.05). Conclusion VEGF and DLL4 are highly expressed in renal cell carcinoma,and are closely related to clinical stage,lymph node metas-tasis and prognosis,which can be used as reference indexs for clinical diagnosis and prognosis judgment of renal cell carci-noma.

OBJECTIVE:The purpose of the current work was to comparatively assess 1470 nm diode laser enucleation of the prostate (DiLEP) and plasmakinetic resection of the prostate (PKRP) for treating benign prostatic hyperplasia (BPH). PATIENTS AND METHODS:From January 2016 to March 2017, 157 individuals with bladder outflow obstruction caused by BPH were randomized to DiLEP and PKRP groups, for prospective analysis. Of these, 152 cases were evaluated before operation and at 3, 6, and 12 months postsurgery. Patient baseline properties, presurgery data, and postsurgical outcomes were comparatively assessed, as well as complications. RESULTS:There were no significant preoperative differences between surgical groups. DiLEP-treated cases showed remarkable reduced operative time, postsurgical bladder irrigation time, catheterization duration, and hospital stay compared with the PKRP group (P < 0.001). Hemoglobin amount decrease was markedly less pronounced after DiLEP (P = 0.004). However, no patients needed blood transfusion in either group. The decrease in sodium level showed no marked differences between the DiLEP and PKRP groups (P = 0.380). In addition, complications were comparable and no significant differences in both groups. At 3, 6, and 12 months, International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and postvoid residual (PVR) were similar in both groups (P > 0.05). CONCLUSIONS:DiLEP and PKRP are similar in efficacy and safety for relieving obstruction and low urinary tract symptoms. Compared with PKRP, DiLEP has decreased risk of hemorrhage, operative time, bladder irrigation time, catheterization duration, and hospital stay. However, IPSS, QoL, Qmax, and PVR were similar for both procedures within 12 postoperative months.